Miguel Coego Rios
Finanzdirektor/CFO bei CENTOGENE N.V.
Vermögen: 51 691 $ am 31.05.2024
Profil
Jose Miguel Coego Rios is currently the Chief Financial Officer, Legal, IT & MD at Centogene NV.
Previously, he held the position of Chief Financial Officer-EMEA & Vice President at Mundipharma International Ltd.
He also served as the Chief Financial Officer-LATAM & GM-Andrea Region at Shire Plc from 2011 to 2019.
Additionally, he worked as the Vice President & General Manager-South Europe at Orphazyme A.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
CENTOGENE NV
0,48% | 15.05.2024 | 139 329 ( 0,48% ) | 51 691 $ | 31.05.2024 |
Aktive Positionen von Miguel Coego Rios
| Unternehmen | Position | Beginn |
|---|---|---|
| CENTOGENE N.V. | Finanzdirektor/CFO | 31.03.2022 |
Ehemalige bekannte Positionen von Miguel Coego Rios
| Unternehmen | Position | Ende |
|---|---|---|
| SHIRE | Corporate Officer/Principal | 01.01.2019 |
Mundipharma International Ltd.
 Mundipharma International Ltd. Pharmaceuticals: MajorHealth Technology Mundipharma International Ltd. develops and produces pharmaceutical products. It offers analgesics, oncology, respiratory, gastrointestinal, and cardiovascular drugs. The company was founded in 1952 and is headquartered in Cambridge, the United Kingdom. | Corporate Officer/Principal | - |
| ORPHAZYME A/S | Corporate Officer/Principal | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| CENTOGENE N.V. | Commercial Services |
| ORPHAZYME A/S | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Mundipharma International Ltd.
Mundipharma International Ltd. Pharmaceuticals: MajorHealth Technology Mundipharma International Ltd. develops and produces pharmaceutical products. It offers analgesics, oncology, respiratory, gastrointestinal, and cardiovascular drugs. The company was founded in 1952 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Shire Plc
 Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland. | Health Technology |
